The DOI matches its Crossref record; 248 of the 248 references it cites were found in a registry or an index.
Prognostic and predictive biomarkers in breast cancer: Past, present and future
Abstract
Following a diagnosis of breast cancer, the most immediate challenges in patient management are the determination of prognosis and identification of the most appropriate adjuvant systemic therapy. Determining prognosis can best be addressed with a combination of traditional clinicopathological prognostic factors, biomarkers such as HER2/neu and specific multigene genes tests. Amongst the best validated prognostic multigene tests are uPA/PAI1, Oncotype DX and MammaPrint. Oncotype DX and MammaPrint, may be used for predicting outcome and aiding adjunct therapy decision making in patients with ER-positive, HER2-negative breast cancers that are either lymph node-negative or node positive (1-3 metastatic nodes), while uPA/PAI-1 may be similarly used in ER-positive, lymph node-negative patients. For selecting likely response to endocrine therapy, both estrogen receptors (ER) and progesterone receptors (PR) should be measured. On the other hand, for identifying likely response to anti-HER2 therapy, determination of HER2 gene amplification or overexpression is necessary. To identify new prognostic and predictive biomarkers for breast cancer, current research is focusing on tumor and circulating DNA (ctDNA) and RNA (e.g., micro RNAs) and circulating tumor cells. A promising ctDNA biomarker is the mutational status of ER (ESR1) for predicting the emergence of resistance to aromatase inhibitors. Challenges for future research include the identification of biomarkers for predicting response to radiotherapy and specific forms of chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–248 of 248
Albanell, J., Svedman, C., Gligorov, J., Holt, S., Bertelli, G., Blohmer, J., Rouzier, R., Lluch, A. M., & EIERMANN, W. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.027 · Cited by 71
miR-342 is associated with estrogen receptor-α expression and response to tamoxifen in breast cancer
He, Y., WU, J.-Z., Ji, M., Ma, T., Qiao, E., Ma, R., & Tang, J. (2013) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2013.915 · Cited by 70
Jansen, M. P. H. M., Reijm, E. A., Sieuwerts, A. M., Ruigrok-Ritstier, K., Look, M. P., Rodríguez-González, F. G., Heine, A. A. J., Martens, J. W. M., Sleijfer, S., Foekens, J. A., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1877-4 · Cited by 70
Zhu, Y., Wu, J., Li, S., Ma, R., Cao, H., Ji, M., Jing, C., & Tang, J. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000354521 · Cited by 69
A Prognostic Model of Triple-Negative Breast Cancer Based on miR-27b-3p and Node Status
Shen, S., Sun, Q., Liang, Z., Cui, X., Ren, X., Chen, H., Zhang, X., & Zhou, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100664 · Cited by 67
Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer
Kang, M.-H., Jeong, K., Kim, W. Y., Lee, H. J., Gong, G., Suh, N., Győrffy, B., Kim, S., Jeong, S.-Y., Mills, G. B., et al. (2016) · Oncogene · doi:10.1038/onc.2016.327 · Cited by 66
Pierga, J., Petit, T., Lévy, C., Ferrero, J.-., Campone, M., Gligorov, J., Lerebours, F., Roche, H. H., Bachelot, T., Charafe‐Jauffret, E., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1705 · Cited by 65
Sonnenblick, A., Brohée, S., Fumagalli, D., Vincent, D., Venet, D., Ignatiadis, M., Salgado, R., den Eynden, G. V., Rothé, F., Desmedt, C., et al. (2015) · BMC Medicine · doi:10.1186/s12916-015-0416-2 · Cited by 64
miR-342 Regulates BRCA1 Expression through Modulation of ID4 in Breast Cancer
Crippa, E., Lusa, L., Cecco, L. D., Marchesi, E., Călin, G. A., Radice, P., Manoukian, S., Peissel, B., Daidone, M. G., Gariboldi, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087039 · Cited by 63
Bidard, F., Belin, L., Delaloge, S., Lerebours, F., Ngô, C., Reyal, F., Alran, S., Giacchetti, S., Marty, M. E., Lebofsky, R., et al. (2013) · International Journal of Breast Cancer · doi:10.1155/2013/130470 · Cited by 59
Salmen, J., Neugebauer, J. K., Fasching, P. A., Haeberle, L., Huober, J., Wöckel, A., Rauh, C., Schütz, F., Weissenbacher, T. M., Kost, B., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3130-4 · Cited by 59
Lü, L., Fang, J., Zhao, H., & Ma, X. (2015) · Biotechnology Letters · doi:10.1007/s10529-015-1941-y · Cited by 57
MicroRNA‐548j functions as a metastasis promoter in human breast cancer by targeting Tensin1
Zhan, Y., Liang, X., Li, L., Wang, B., Ding, F., Li, Y., Wang, X., Zhan, Q., & Liu, Z. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.02.002 · Cited by 56
Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial
Ignatiadis, M., Rack, B. K., Rothé, F., Riethdorf, S., Decraene, C., Bonnefoi, H. R., Dittrich, C., Messina, C. G. M., Beauvois, M., Trapp, E. K., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.04.024 · Cited by 56
Molecular Testing in Breast Cancer
Paoletti, C., & Hayes, D. F. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-070912-143853 · Cited by 53
MicroRNA-203 Regulates Growth and Metastasis of Breast Cancer
Zhao, S., Han, J., Zheng, L., Yang, Z., Zhao, L., & Lv, Y. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000430331 · Cited by 52
Stoetzer, O. J., Fersching, D. M. I., Salat, C., Steinkohl, O., Gabka, C. J., Hamann, U., Braun, M., Feller, A. M., Heinemann, V., Siegele, B., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.04.013 · Cited by 52
Hicks, M. J., Macrae, E. R., Abdel‐Rasoul, M., Layman, R. M., Friedman, S., Querry, J., Lustberg, M. B., Ramaswamy, B., Mrózek, E., Shapiro, C. L., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0334 · Cited by 52
Tang, Y., Zhou, X., Ji, J., Chen, L., Cao, J., Luo, J., & Zhang, S. (2015) · The International Journal of Biological Markers · doi:10.5301/jbm.5000160 · Cited by 50
MiR-34a is up-regulated in response to low dose, low energy X-ray induced DNA damage in breast cells
Stankevicins, L., da Silva, A. P. A., dos Passos, F. V., Ferreira, E. D. S., Ribeiro, M. C. M., David, M., Pires, E. J., Ferreira-Machado, S. C., Vassetzky, Y. S., de Almeida, C. E., et al. (2013) · Radiation Oncology · doi:10.1186/1748-717x-8-231 · Cited by 49
Heuckmann, J. M., & Thomas, R. K. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv184 · Cited by 48
miR-30e* is an independent subtype-specific prognostic marker in breast cancer
D’Aiuto, F., Callari, M., Dugo, M., Merlino, G., Musella, V., Miodini, P., Paolini, B., Cappelletti, V., & Daidone, M. G. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.206 · Cited by 47
Overexpression of MicroRNA-200c Predicts Poor Outcome in Patients with PR-Negative Breast Cancer
Tuomarila, M., Luostari, K., Soini, Y., Kataja, V. V., Kosma, V., & Mannermaa, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109508 · Cited by 45
Wang, Y., Zhang, Y., Pan, C., Ma, F., & Zhang, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118647 · Cited by 45
MicroRNA-16 sensitizes breast cancer cells to paclitaxel through suppression of IKBKB expression
Tang, X., Jin, L., Cao, P., Cao, K., Huang, C., Luo, Y., Ma, J., Shen, S., Tan, M., Li, X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8056 · Cited by 45
Yeo, B. J., Zabaglo, L. A., Hills, M., Dodson, A. R., Smith, I., & Dowsett, M. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.222 · Cited by 44
Emerging Therapeutic Options for HER2-Positive Breast Cancer
Martín, M., & López‐Tarruella, S. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159167 · Cited by 41
Nordenskjöld, A. E., Fohlin, H., Fornander, T., Löfdahl, B., Skoog, L. K., & Stål, O. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4007-5 · Cited by 41
Prognostic Role of MicroRNA-210 in Various Carcinomas: A Systematic Review and Meta-Analysis
Li, M., Ma, X., Li, M., Zhang, B., Huang, J., Liu, L., & Wei, Y. (2014) · Disease Markers · doi:10.1155/2014/106197 · Cited by 40
Banys-Paluchowski, M. J., Krawczyk, N., & Fehm, T. N. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00255 · Cited by 40
Kuijer, A., Straver, M. E., den Dekker, B. M., van Bommel, A. C. M., Elias, S. G., Smorenburg, C. H., Wesseling, J., Linn, S. C., Rutgers, E. J. T., Siesling, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3959 · Cited by 39
(2018) · Elsevier eBooks · doi:10.1016/c2017-0-01382-4 · Cited by 39
Fallahi, M., Amelio, A. L., Cleveland, J. L., & Rounbehler, R. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115517 · Cited by 38
The Clinicopathological Significance of MicroRNA-155 in Breast Cancer: A Meta-Analysis
Zeng, H., Fang, C., Nam, S., Cai, Q., & Long, X. (2014) · BioMed Research International · doi:10.1155/2014/724209 · Cited by 35
A MicroRNA Expression Signature In Taxane-anthracycline-Based Neoadjuvant Chemotherapy Response
Zheng, Y., Li, S., Boohaker, R. J., Liu, X., Yufen, Z., Zhai, L., Li, H., Gu, F., Fan, Y., Lang, R., et al. (2015) · Journal of Cancer · doi:10.7150/jca.11616 · Cited by 31
Pan, F., Mao, H., Deng, L., Li, G., & Geng, P. (2014) · PubMed · Cited by 27
Kasimir‐Bauer, S., Reiter, K., Aktas, B., Bittner, A., Weber, S., Keller, T., Kimmig, R., & Hoffmann, O. (2016) · Scientific Reports · doi:10.1038/srep26355 · Cited by 26
Seguí, M. Á., Crespo, C., Cortés, J., Lluch, A. M., Brosa, M., Becerra, V., Chiavenna, S. M., & Gracia, A. (2014) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2014.957185 · Cited by 24
Petrović, N., Kolaković, A., Stanković, A., Lukić, S., Řami, A., Ivković, M., & Mandušić, V. (2016) · Cancer Biomarkers · doi:10.3233/cbm-160577 · Cited by 24
Jacobs, V. R., Kates, R. E., Kantelhardt, E. J., Vetter, M., Wuerstlein, R., Fischer, T., Schmitt, M., Jaenicke, F., Untch, M., Thomssen, C., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2496-z · Cited by 23
PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum
Goel, S., & Krop, I. E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw246 · Cited by 22
ApoptomiRs of Breast Cancer: Basics to Clinics
Sharma, S., Patnaik, P. K., Aronov, S., & Kulshreshtha, R. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00175 · Cited by 22
Fung, F., Cornacchi, S. D., Vanniyasingam, T., Dao, D., Thabane, L., Simunovic, M. R. I., Hodgson, N., O’Brien, M. A., Reid, S., Heller, B., et al. (2016) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2016.03.016 · Cited by 19
Chromatin immunoprecipitation: advancing analysis of nuclear hormone signaling
Vinckevicius, A., & Chakravarti, D. (2012) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0016 · Cited by 18
Identification of targets of miRNA-221 and miRNA-222 in fulvestrant-resistant breast cancer
Liu, P., Sun, M., Jiang, W., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.5180 · Cited by 14
Chandarlapaty, S., Sung, P., Chen, D., He, W., Samoila, A., You, D., Bhatt, T., Patel, P. T., Voi, M., Gnant, M., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-s2-07 · Cited by 13
Sledge, G. W. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35955-9.00056-8 · Cited by 10
Park, H. S., Sohn, J., Kim, S. I., Park, S., Park, H. S., Gho, S. G., Chung, H. C., Paik, S., & Kim, G. M. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4175-y · Cited by 4
Cited by
Predicting cancer outcomes with radiomics and artificial intelligence in radiology
Bera, K., Braman, N., Gupta, A., Velcheti, V., & Madabhushi, A. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00560-7 · Cited by 819
Mahmood, N., Mihalcioiu, C., & Rabbani, S. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00024 · Cited by 478
Artificial intelligence (AI) and big data in cancer and precision oncology
Dlamini, Z., Francies, F. Z., Hull, R., & Marima, R. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.08.019 · Cited by 398
Artificial intelligence in oncology
Shimizu, H., & Nakayama, K. I. (2020) · Cancer Science · doi:10.1111/cas.14377 · Cited by 388
Metadata
- Authors
- Nicolini, A., Ferrari, P., & Duffy, M. J.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 52
- Issue
- Pt 1
- Pages
- 56-73
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2752658156
- Cited by
- 424
- References
- 248
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.